Fang Liu

Fang Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LLLan-Qing Liang
Lan-Qing Liang
LMLing-Ling Meng
Ling-Ling Meng
BCBo-Ning Cai
Bo-Ning Cai
ZCZe-Ping Cui
Ze-Ping Cui
NMNa Ma
Na Ma
FLFang Liu
Fang Liu
Changes in the nutritional status of nine vitamins in patients with esophageal cancer during chemotherapy

2 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
BCBoning Cai
Boning Cai
XLXiaomo Li
Xiaomo Li
XHXiang Huang
Xiang Huang
TMTonghui Ma
Tonghui Ma
BQBaolin Qu
Baolin Qu
FLFang Liu
Fang Liu
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for advanced non-small-cell lung cancer (NSCLC) patients. However, most patients will eventually develop resistance. For EGFR-TKI resistance mediated by MET amplification, the combination of EGFR and MET TKIs has shown promising results in early clinical trials. However, acquired resistance to MET inhibitors forms a formidable challenge to this dual blockade approach. Here, we presented an NSCLC patient with EGFR exon 19 deletion (ex19del) who was resistant to first-line erlotinib treatment but responded to chemotherapy. Given the finding of MET overexpression/amplification after disease progression, the patient received gefitinib plus crizotinib with a partial response. Her disease progressed again, and molecular testing revealed a novel MET Y1230H mutation and a PD-L1 TPS score of 75%. She received a salvage regime consisting of gefitinib, cabozantinib, and pembrolizumab with a partial response. Since we now know that EGFR ex19del NSCLC patients generally do not respond to PD-1 blockade therapy, this response is more likely the contribution from gefitinib plus cabozantinib. Therefore, sequential use of type I and II MET inhibitors in EGFR/MET dual blockade may be an effective therapeutic option for EGFR-mutant, MET-amplified NSCLC.

7 November 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
HWHong-Chi Wang
Hong-Chi Wang
XHXiang Huang
Xiang Huang
JCJing Chen
Jing Chen
YLYe Li
Ye Li
YCYang Cong
Yang Cong
FLFang Liu
Fang Liu
Inflammatory bowel disease (IBD) has as a main characteristic the exacerbation of the immune system against enterocytes, compromising the individual’s intestinal microbiota. This inflammatory cascade causes several nutritional deficiencies, which further compromise immunological functioning and, as a result, worsen the prognosis. This vicious cycle can be interrupted as the patient’s dietary pattern meets their needs according to their clinical condition, acting directly on the inflammatory process of IBD through the interaction of food, intestinal microbiota, and epigenome. Specific nutritional intervention for IBD has a crucial role in preventing and managing disease activity. This review addresses epigenetic modifications through dietary compounds as a mechanism for modulating the intestinal microbiota of patients with IBD.

1 June 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
PZPei Zhang
Pei Zhang
XHXiaobin Hou
Xiaobin Hou
BCBoning Cai
Boning Cai
WYWei Yu
Wei Yu
JCJing Chen
Jing Chen
FLFang Liu
Fang Liu
Background: Treatments for patients with advanced esophageal cancer are still limited. Pembrolizumab has demonstrated antitumor activity in patients with advanced esophageal cancer in previous studies. Few studies have assessed safety and efficacy in routine clinical practice. We investigated the real-world outcomes of pembrolizumab for patients with advanced esophageal cancer. Methods: This retrospective, observational study collected 57 advanced esophageal squamous cell carcinoma (ESCC) patients from October 1, 2019 to October 1, 2021, 57 who received different patterns of treatments according to the staging were collected. Briefly, patients diagnosed with locally advanced and surgically resectable ESCC received neoadjuvant therapy followed by surgery. For patients with locally advanced, unresectable ESCC, the treatment regimen including chemoradiotherapy combined with pembrolizumab was performed. Patients with metastatic ESCC or those not suitable for radiotherapy received pembrolizumab plus chemotherapy. Safety was assessed in all treated patients. The objective response rate (ORR) was used to evaluate the efficacy. Results: The ORR was 74.1% (40/54) among all patients. The most common adverse events (AEs) were leukopenia (36.8%, 21/57), nausea (28.1%, 16/57), and thrombocytopenia (14%, 8/57). Grade III and higher AEs were observed in 9 of the 57 patients (15.8%). Conclusions: For patients with advanced ESCC, combined treatment with pembrolizumab was effective and safe. Multicenter studies should be carried out for further confirmation.

15 November 2021 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
MYMao-Hui Yan
Mao-Hui Yan
FLFang Liu
Fang Liu
BQBao-Lin Qu
Bao-Lin Qu
BCBo-Ning Cai
Bo-Ning Cai
WYWei Yu
Wei Yu
XDXiang-Kun Dai
Xiang-Kun Dai
Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

16 August 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
NXNian-Jun Xiao
Nian-Jun Xiao
TCTing-Ting Cui
Ting-Ting Cui
FLFang Liu
Fang Liu
WLWen Li
Wen Li
With the advance of invasive interventions, the treatment model for infected necrotizing pancreatitis (INP) has shifted from open surgery to the step-up minimally invasive treatment. Late intervention, originating from the open surgery era, has been questioned in the minimally invasive period. With the emergence of new high-quality evidence about the timing for intervention, it seems to be increasingly apparent that, even in the age of minimal invasiveness, “late intervention” waiting for the necrotic collections to be encapsulated is still necessary. This opinion review mainly discusses the intervention timing for INP.